24-month follow-up of a randomised non-inferiority trial in 150 patients with benign prostatic obstruction: ThuFLEP was non-inferior to HoLEP for IPSS and QoL (median IPSS 21 to 3 vs 20 to 4); 3 late adverse events, all after ThuFLEP, not significant.
RCTn = 150
Filzmayer et al. Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial